You just read:

Xencor Reports Complete Data Results from XmAb7195 Phase 1a Trial Showing Rapid Reduction of Serum IgE in High IgE Atopic Subjects at ATS 2016 International Conference

News provided by

Xencor, Inc.

18 May, 2016, 12:00 ET